Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients
NCT ID: NCT02307643
Last Updated: 2017-06-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
17 participants
INTERVENTIONAL
2015-02-28
2017-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Participants
NCT05278663
A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus
NCT01127321
A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
NCT07011043
A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus
NCT07299422
Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects
NCT01534403
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part 1
MT-1303 Low dose+Corticosteroid
MT-1303 Low dose
Part 2-A
MT-1303 High dose+Corticosteroid
MT-1303 High dose
Part 2-B
MT-1303 Low dose+Corticosteroid+Immunosuppressant
MT-1303 Low dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MT-1303 Low dose
MT-1303 High dose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presence of at least one of the following items: positive anti ds-DNA antibodies, low complement levels, and so on.
* Stable doses of corticosteroids
Exclusion Criteria
20 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mitsubishi Tanabe Pharma Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tsutomu Takeuchi, MD
Role: STUDY_CHAIR
Keio University Hospital
Yoshiya Tanaka, MD
Role: STUDY_DIRECTOR
University of Occupational and Environmental Health
Kazuoki Kondo, MD
Role: STUDY_DIRECTOR
Mitsubishi Tanabe Pharma Corporation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Inverstigational site
Bunkyō City, , Japan
Inverstigational site
Chiba, , Japan
Inverstigational site
Chūōku, , Japan
Inverstigational site
Fuchu-shi, , Japan
Investigational site
Fukuoka, , Japan
Inverstigational site
Kawagoe-shi, , Japan
Inverstigational site
Maebashi, , Japan
Inverstigational site
Meguro-ku, , Japan
Investigational site
Narashino-shi, , Japan
Investigational site
Sendai, , Japan
Inverstigational site
Shimotsuga-gun, , Japan
Inverstigational site
Shinjuku-ku, , Japan
Inverstigational site
Tsukuba, , Japan
Investigational site
Urayasu-shi, , Japan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tanaka Y, Kondo K, Ichibori A, Yanai Y, Susuta Y, Inoue S, Takeuchi T. Amiselimod, a sphingosine 1-phosphate receptor-1 modulator, for systemic lupus erythematosus: A multicenter, open-label exploratory study. Lupus. 2020 Dec;29(14):1902-1913. doi: 10.1177/0961203320966385. Epub 2020 Oct 28.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MT-1303-J03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.